Home › Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
 

Keywords :   


Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes

2013-03-28 09:57:29| dairynetwork Home Page

Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.

Tags: the of treatment trial

Category:Agriculture and Forestry

Latest from this category

All news
22.11Trump expected to tab Kelly Loeffler for Secretary of Agriculture
22.11Hay supply is likely up, but winter feed costs still matter
22.11Future plans for US SHIP and USDA's role explored
22.11Strategy for increasing feed efficiency for cows
22.11Top 3 myths of cattle marketing
22.11Carcass management workshop gets pork producers FAD prepared
22.11Are we close to eliminating Mycoplasma hyopneumoniae from the U.S. swine herd?
22.11Costa to challenge Scott for top House Agriculture Democrat role
Agriculture and Forestry »
23.11 10
23.11MusyaPop210
23.11S.H.Figuarts
23.11 Kanye West
23.11
23.111TC
23.11
23.11abe
More »